Jiangsu Hengrui Medicine's 3Q Margins Likely Improved -- Market Talk

Dow Jones2023-10-17

0313 GMT - Jiangsu Hengrui Medicine is likely to report improvement in 3Q margins thanks to rising contribution from innovative drugs and selling expenses saved under the ongoing anticorruption campaign in China, Nomura analyst Jialin Zhang says in a research note. Zhang expects Hengrui's 3Q revenue to rise 5% on year on rising sales of innovative oncology drugs, partially offset by a relative high base last year. Nomura trims its 2023 and 2024 revenue forecasts by 0.5% and 0.6%, respectively, to factor in the ongoing anticorruption campaign's impact on revenue. Nomura maintains a neutral call on Hengrui but lowers its target price to CNY49.24 from CNY50.19 due to weaker revenue forecasts. Shares are last 1.0% lower at CNY43.74. (sherry.qin@wsj.com)

(END) Dow Jones Newswires

October 16, 2023 23:13 ET (03:13 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2376173094?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-10-17 11:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2376173094","market":"us","top_or_hot":-1,"title":"Jiangsu Hengrui Medicine's 3Q Margins Likely Improved -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0313 GMT - Jiangsu Hengrui Medicine is likely to report improvement in 3Q margins thanks to rising contribution from innovative drugs and selling expenses saved under the ongoing anticorruption campaign in China, Nomura analyst Jialin Zhang says in a research note. Zhang expects Hengrui's 3Q revenue to rise 5% on year on rising sales of innovative oncology drugs, partially offset by a relative high base last year. Nomura trims its 2023 and 2024 revenue forecasts by 0.5% and 0.6%, respectively, to factor in the ongoing anticorruption campaign's impact on revenue. Nomura maintains a neutral call on Hengrui but lowers its target price to CNY49.24 from CNY50.19 due to weaker revenue forecasts. Shares are last 1.0% lower at CNY43.74. (sherry.qin@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 16, 2023 23:13 ET (03:13 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangsu Hengrui Medicine's 3Q Margins Likely Improved -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangsu Hengrui Medicine's 3Q Margins Likely Improved -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-17 11:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>0313 GMT - Jiangsu Hengrui Medicine is likely to report improvement in 3Q margins thanks to rising contribution from innovative drugs and selling expenses saved under the ongoing anticorruption ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2376173094","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2376173094","pubTimestamp":1697512380,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0313 GMT - Jiangsu Hengrui Medicine is likely to report improvement in 3Q margins thanks to rising contribution from innovative drugs and selling expenses saved under the ongoing anticorruption campaign in China, Nomura analyst Jialin Zhang says in a research note. Zhang expects Hengrui's 3Q revenue to rise 5% on year on rising sales of innovative oncology drugs, partially offset by a relative high base last year. Nomura trims its 2023 and 2024 revenue forecasts by 0.5% and 0.6%, respectively, to factor in the ongoing anticorruption campaign's impact on revenue. Nomura maintains a neutral call on Hengrui but lowers its target price to CNY49.24 from CNY50.19 due to weaker revenue forecasts. Shares are last 1.0% lower at CNY43.74. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","BK0196":"行业龙头","BK0239":"医药制造","BK0012":"证金概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0188":"融资融券","BK0060":"抗癌","BK0028":"国家队","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK0183":"MSCI概念","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC"},"translate_title":"江苏恒瑞医药第三季度利润率可能提高——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9},"content_text":"0313 GMT - Jiangsu Hengrui Medicine is likely to report improvement in 3Q margins thanks to rising contribution from innovative drugs and selling expenses saved under the ongoing anticorruption campaign in China, Nomura analyst Jialin Zhang says in a research note. Zhang expects Hengrui's 3Q revenue to rise 5% on year on rising sales of innovative oncology drugs, partially offset by a relative high base last year. Nomura trims its 2023 and 2024 revenue forecasts by 0.5% and 0.6%, respectively, to factor in the ongoing anticorruption campaign's impact on revenue. Nomura maintains a neutral call on Hengrui but lowers its target price to CNY49.24 from CNY50.19 due to weaker revenue forecasts. Shares are last 1.0% lower at CNY43.74. (sherry.qin@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 16, 2023 23:13 ET (03:13 GMT)\n\n\n  Copyright (c) 2023 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2376173094"}